Vicore Pharma

Carl-Johan Dalsgaard will continue in his current role until a successor is in place. He will work closely with the Board to ensure a smooth and efficient transition and to support the Company.

“Carl-Johan has done a tremendous work over many years which has transformed Vicore into a late phase clinical stage company,” said Jacob Gunterberg, chairman of the Board of Directors. “Carl-Johan’s experience and agility have benefitted Vicore and inspired the team, developing C21 as a potentially transformative therapy for the treatment of Idiopathic Pulmonary Fibrosis as well as expanding our pipeline with follow-on molecules. With the recent announcement of exciting data from the Phase 2a AIR trial in IPF and following the completion of a successful financing, Carl-Johan will be handing over the company in very good shape.”

The Company considers the CEO recruitment process to constitute inside information and consequently discloses this information so it can be included in the prospectus published due to the admission to trading of shares from the directed share issue announced in June 2023. Such prospectus is expected to be published on or around July 7, 2023.

For further information, please contact:
Jacob Gunterberg, Chairman, e-mail: jacob.gunterberg@vicorepharma.com

This information constitutes inside information which Vicore Pharma Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on July 5, 2023 at 11:30 CEST.

About Vicore Pharma Holding AB (publ)
Vicore is an innovative Swedish clinical-stage pharmaceutical company unlocking the potential of a new class of drugs to stop disease progression and restore function. The company is establishing a portfolio in rare lung diseases including idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH). C21 is a first-in-class orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in a phase 2a study of IPF. C21 is protected by US and European orphan drug designation. A variety of patents have been filed to provide further protection for C21, out to 2040 and onwards. Almee™ (an investigational medical device in clinical development) is a digital therapeutic (DTx) based on cognitive behavioral therapy (CBT) created to address the psychological impact of living with pulmonary fibrosis. Inhaled IMID is a new formulation and delivery route of thalidomide targeting the severe cough associated with IPF. Using its unique expertise in the ATRAG biology Vicore is further fueling its pipeline with several new small molecule drug assets, with long patent life and for a variety of indications, some of which could be partnered while others may be taken to the market by Vicore.

The company’s shares (VICO) are listed on Nasdaq Stockholm’s main market. For more information, see www.vicorepharma.com.